SCHEMBL26074208

SCHEMBL26074208

COC(=O)c1cc(-c2ccc(-c3ccc(N(C)C)cc3)cc2)nc2ccc(C(F)(F)F)cc12

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PLA2G2A P14555 7/20 0.56
▸ ALDH1A1 P00352 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ CYP3A4 P08684 2/20 0.48
▸ DHODH Q02127 3/20 0.45
▸ RUVBL1 Q9Y265 1/20 0.45
▸ MAPT P10636 4/20 0.44
▸ GAA P10253 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ KDM1A O60341 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23590241 0.89 HSD17B10 (0.53) ALDH1A1KDM4ECYP3A4DHODHGAA
SCHEMBL26074194 0.84 PLA2G2A (0.55) PLA2G2AALDH1A1KDM4EMEN1KMT2A
SCHEMBL26075602 0.84 PLA2G2A (0.62) PLA2G2AALDH1A1KDM4EMEN1KMT2A
SCHEMBL26074163 0.83 PLA2G2A (0.59) PLA2G2AALDH1A1KDM4EMEN1KMT2A
SCHEMBL26074129 0.82 PLA2G2A (0.74) PLA2G2AALDH1A1KDM4EMEN1KMT2A
SCHEMBL26074173 0.81 PLA2G2A (0.56) PLA2G2AALDH1A1KDM4EMEN1KMT2A
SCHEMBL26074181 0.80 PLA2G2A (0.52) PLA2G2AALDH1A1KDM4EMEN1KMT2A
SCHEMBL26074143 0.80 PLA2G2A (0.72) PLA2G2AALDH1A1KDM4EMEN1KMT2A
SCHEMBL26074176 0.79 PLA2G2A (0.53) PLA2G2AALDH1A1KDM4EMEN1KMT2A
SCHEMBL26074138 0.79 PLA2G2A (0.71) PLA2G2AALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD PLA2G2A 1679/4885ALDH1A1 88/4885KDM4E 1396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback